Genomind continues relationship with the American Psychiatric Nurses Association
CHALFONT, PA – October 9, 2013 – Genomind, a personalized medicine company, is pleased to announce their participation at the American Psychiatric Nurses Association (APNA) Annual Conference, to be held October 9-12 in San Antonio, Texas. This will be Genomind’s third year attending and exhibiting with the organization.
The APNA is comprised of over 9,000 members, and they are committed to the practice of psychiatric mental health nursing, health and wellness promotion through identification of mental health issues, prevention of mental health problems and the care and treatment of person with psychiatric disorders. Genomind continues to serve this clinical community with the Genecept™ Assay, their core product, a saliva-based genetic test used to help inform clinician treatment decisions.
“Genomind is committed to the advancement of personalized medicine for the treatment of psychiatric disorders, and is a strong supporter of APNA,” said Dr. Jay Lombard, Chief Scientific Officer and Medical Director. “Genomind values the relationships with the many psychiatric nurse practitioners using the Genecept Assay, and we plan to share new data and findings with them at the conference.”
The patient’s genetic data and informative report provided by the Assay, combined with Genomind’s clinician consultation included with every test, improves the clinician-patient relationship, contributes to cost containment, and enhances the clinician’s reputation for bringing the most advanced science to the clinic.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/ .
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind